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Abstract
Heart failure is becoming increasingly prevalent in the United States and is a significant cause of 
morbidity and mortality. Several therapies are currently available to treat this chronic illness; 
however, clinical response to these treatment options exhibit significant interpatient variation. It is 
now clearly understood that genetics is a key contributor to diversity in therapeutic response, and 
evidence that genetic polymorphisms alter the pharmacokinetics, pharmacodynamics, and clinical 
response of heart failure drugs continues to accumulate. This suggests that pharmacogenomics has 
the potential to help clinicians improve the management of heart failure by choosing the safest and 
most effective medications and doses. Unfortunately, despite much supportive data, 
pharmacogenetic optimization of heart failure treatment regimens is not yet a reality. In order to 
attenuate the rising burden of heart failure, particularly in the context of the recent paucity of new 
effective interventions, there is an urgent need to extend pharmacogenetic knowledge and leverage 
these associations in order to enhance the effectiveness of existing heart failure therapies. The 
present review focuses on the current state of pharmacogenomics in heart failure and provides a 
glimpse of the aforementioned future needs.
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INTRODUCTION
Heart failure has reached epidemic proportions. Approximately 5 million adults have heart 
failure in the United States with recent projections suggesting that by 2030, the prevalence 
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of this syndrome will increase another 25%. 1 Thus, heart failure has tremendous impact on 
the health care system and constitutes a major medical and societal burden. Heart failure is 
characterized by insufficient cardiac performance to meet metabolic requirements or 
accommodate systemic venous return. 2 The body’s neurohormonal system including the 
renin-angiotensin-aldosterone system (RAAS) and the sympathetic nervous system (SNS) is 
activated in order to compensate for these deficiencies 2 but activation of these systems 
contribute to worsening heart failure, worsened quality of life, and poor outcomes such as 
the need for a heart transplant, or sudden cardiac death. 3 Evidence-based medical therapies 
that suppress these responses can substantially reduce the progression of this syndrome. 4–6 
Accordingly, comprehensive heart failure management guidelines from both the American 
College of Cardiology (ACC)/American Heart Association (AHA) and the Heart Failure 
Society of America (HFSA) recommend specific pharmacological management, mostly 
focused on neurohormonal suppression, to improve outcomes in all patients with heart 
failure and reduced ejection fraction. 7,8 β blockers and angiotensin converting enzyme 
(ACE)-inhibitors are considered the foundation, but evidence has shown important roles for 
other therapies which help delay progression of heart failure and reduce mortality including 
angiotensin receptor blockers (ARB)s, aldosterone antagonists, hydralazine/isosorbide 
combination, and even device therapies such as implanted defibrillators and cardiac 
resynchronization therapy (CRT). 7,8 In addition, while there is no evidence for mortality 
benefits with loop diuretics and digoxin, these agents are indispensable, improving 
symptoms and possibly reducing hospitalizations. 9,10 It is thus evident that heart failure 
patients are currently subjected to a multiplicity of medications to achieve maximum benefit 
and optimized outcomes. This polypharmacy in health failure patients is associated with 
increased risk of toxicity, drug interactions, and poor compliance. 11 Current guidelines do 
offer some advice regarding tailoring of therapy on clinical grounds; for example, the HFSA 
guidelines recommend that factors such as age, ethnicity, heart failure severity, renal 
function, and serum potassium should be used to choose which of the many agents a heart 
failure patient should receive in his or her regimen. 7 However, even in patients who appear 
to have similar clinical factors, a great deal of variability exists in response to treatment. 12 
Genetic variability in response to heart failure treatment exists 13 and genetic information 
may complement conventional clinical information in tailoring therapy to an individual 
patient, ultimately improving outcomes. The present review focuses on available data from 
pharmacogenomic studies in heart failure medications, particularly focusing on new 
developments over the past 2 years (earlier literature has been nicely described 
elsewhere 14,15), summarized by medication class. Proof-of-principle findings are presented 
that are important to be aware of, but actionable genetic testing to guide therapeutic choices 
in heart failure remains limited to date. Thus, the review also shows that further work in this 
area is needed before the clinical implementation of heart failure pharmacogenomics 
becomes a reality, and we provide a glimpse of the future needs and directions.
BETA ADRENERGIC ANTAGONISTS
The role of the adrenergic signaling pathway of the SNS in heart failure is characterized by a 
vicious cycle in which chronic stimulation of the adrenergic receptor (AR) by circulating 
catecholamines norepinephrine (NE) and epinephrine promotes cardiac dysfunction that 
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results in the release of more adrenergic-stimulating catecholamines and further disease 
progression. 16 While the sub-cellular mechanism of action is not completely elucidated, it is 
clear that β blockers work by suppression of the adrenergic pathway and interruption of this 
vicious cycle. 17 Due to evidence of survival benefit, β blockers have been a mainstay of 
heart failure pharmacotherapy for almost 20 years. 18–20 However, there is great variation in 
response to β blocker therapy including certain subsets of the heart failure population that do 
not receive the same mortality and morbidity benefit. 21,22 Single nucleotide polymorphisms 
(SNPs) in the β1-AR (ADRB1), β2-AR (ADRB2), α2C AR (ADRA2C), and G-protein 
receptor kinase 5 (GRK5) genes of the adrenergic system may partially explain the variable 
effects received from β blockade. In fact, most of the published pharmacogenomic literature 
over the past 2 years concerning heart failure has focused on response to β blockers; thus we 
have given it first and most attention among the drug classes of interest.
β1-AR is the primary pharmacologic target of β blockers. One of the most widely-studied 
polymorphisms for heart failure in ADRB1 is the Arg389Gly variant. Arg389 is associated 
with enhanced adrenergic response to agonist stimulation of β1-AR in vitro 23 and in vivo24. 
Importantly, in a genetic substudy of the β Blocker Evaluation of Survival Trial (BEST), a 
relationship between β1 genotype and mortality response to treatment with the β blocker 
bucindolol was found.25 BEST was a large, randomized, clinical trial testing the efficacy of 
bucindolol in heart failure patients. 26 The trial was terminated prematurely at 2 years due to 
a lack of mortality benefit, though bucindolol significantly improved mortality in the non-
black subset (~75% of the patients).26 As a result of clinical failure in the overall population, 
bucindolol was never approved by the FDA for the treatment of heart failure. Notably, 
bucindolol also acts as a potent sympatholytic in addition to its β blocking properties, 
reducing circulating NE levels to a much greater extent than the β blockers FDA-approved 
for heart failure (e.g. carvedilol and metoprolol succinate).27 This distinct property of 
bucindolol may have reduced NE to deleteriously low levels thereby abrogating cardiac 
contractility and negating any beneficial effects realized through β blockade.25 In the genetic 
substudy, Arg389 homozygotes were found to have a 34% mortality benefit from 
bucindolol. 25 A greater survival rate in patients with this genotype was found when NE 
levels did not decrease compared to baseline, suggesting that an enhanced β blockade affect 
rather than protection from exaggerated sympatholysis may be responsible for reduced 
mortality in this population. In contrast, no clinical benefit was observed in carriers of the 
Gly389 variant. 25 These results were backed up by ex vivo and cell data which also showed 
that enhanced bucindolol response was associated with Arg389. 25 In addition, the results 
may explain racial differences in bucindolol efficacy, as blacks were less likely to carry 
Arg389 compared to non-blacks. 25 However the relatively small difference in allele 
frequencies between racial groups (0.62 in blacks, 0.73 in non-blacks)25 and contradictory 
clinical trial data that do not show variation in response to β blocker therapy across race28, 
suggest that Arg389 does not sufficiently explain racial disparities in bucindolol response.
In addition to the Arg389Gly polymorphism, a variant at codon 49 also has been found to 
influence drug response and clinical adverse outcomes in heart failure patients. Specifically 
in a population of patients with idiopathic dilated cardiomyopathy, Ser49 homozygotes had 
worsened prognosis (death or cardiac transplantation) compared to Gly49 carriers. 29 This 
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association remained present among patients who received β blocker therapy (~39% of the 
population), though the specific β blocker drug patients were taking was not specified. 29 
These data were supported by mechanistic follow-up studies where cells transfected with 
Gly49 had increased sensitivity to metoprolol as well as enhanced catecholamine-induced 
β1-AR desensitization, which is considered a protective response to heart failure 
progression. 30 An expanded clinical follow-up confirmed that Gly49 carriers had better 
survival compared to Ser49 homozygotes, suggesting that higher β blocker doses may be 
warranted in Ser49Ser patients to achieve optimal survival response. 31
ADRB2 has a role in adrenergic signaling in parallel with ADRB1. Indeed, clinical trial data 
from the COMET trial and experimental evidence both suggest that antagonism of β2 AR is 
at least partially responsible for beneficial effects of carvedilol in heart failure. 32,33 ADRB2 
genotype may be important in heart failure pathophysiology and response to β blocker 
therapy. Kaye et al. were able to show that among heart failure patients receiving carvedilol, 
the proportion of patients with a favorable EF response to therapy (≥10% improvement in 
absolute LVEF or ≥5% improvement in absolute FS) was significantly higher in Glu27 
carriers compared to Gln27 homozygous patients34. These findings were validated in a 
larger population.35 Moreover, this effect has been replicated in terms of survival in several 
subsequent studies. 36–38 For example, in a well-treated cohort of advanced heart failure 
patients (81% were receiving β blockers), individuals who carried 2 copies of the ADRB2 
Arg16-Gln27 haplotype were more likely to die or require a heart transplant.38
The ADRA2C gene is responsible for the expression of the α2C AR, an autoreceptor located 
on presynaptic adrenergic neurons, which limits the release of NE through a negative 
feedback system. 39,40 Genetic disruption of α2 ARs in mice resulted in elevated NE levels 
and hearts with significant hypertrophy. 40 The multiple-nucleotide polymorphism α2C322–
325 deletion (Del) similarly increased risk of developing heart failure in black patients 41, 
who have a minor allele frequency of 0.4 compared with 0.04 in whites 42. In a BEST DNA 
substudy, ADRA2C variability surprisingly did not alter baseline levels of NE or the natural 
course of heart failure progression in placebo-treated patients. ADRA2C genotype, however, 
did affect response to bucindolol treatment. 42 Patients who were carriers of the Del allele 
had enhanced norepinephrine reduction from bucindolol compared to wild-type patients. 
Furthermore, bucindolol was found to improve survival only in α2C322–325 wild-type 
homozygotes. 42 Though the precise mechanisms by which ADRA2C genotype impacts the 
ability of bucindolol to reduce NE levels remain unknown, these results are consistent with 
previous findings25 that an exaggerated sympatholytic response to bucindolol is associated 
with reduced survival response to bucindolol.
GRK5 codes for G-protein receptor kinase 5 which desensitize β AR signaling. 43 
Substitution of Gln at the 41st amino acid position with Leu has been found to be a gain-of-
function allele resulting in enhanced desensitization, 43 analogous to an endogenous β 
blocking effect. In a prospective cohort of African American heart failure patients, who have 
10-fold higher allele frequencies of this gain-of-function polymorphism than Caucasians, the 
presence of GRK5 Leu41 was just as protective in preventing cardiac death or heart 
transplant as β blocker use. 43 These findings were recapitulated in an expanded population 
of African American heart failure patients: GRK5 Leu41 improved survival. 44
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Inconsistencies that contradict the above associations between variants in genes of the 
adrenergic system and survival response to β blockers exist in the literature. For example, 
the significant relationship between ADRB1 Arg389Gly genotype and mortality response to 
bucindolol is less clear with the β blocker therapies FDA-approved for heart failure27,45–48; 
however, the aforementioned differences in sympatholytic properties among β blockers may 
explain why the pharmacogenetic association with ADRB1Arg389Gly in heart failure 
patients is inconsistent across members of this drug class. Moreover, De Groote et al. did not 
find a significant genetic association between any of the five aforementioned adrenergic 
receptor polymorphisms and survival in β blocker-treated heart failure patients. 49 An 
investigation in a large registry of heart failure patients with left ventricular dysfunction 
receiving metoprolol or carvedilol showed that individual variants and haplotypes involving 
ADRB1, ADRB2, and ADRA2C were not found to have a significant effect on survival.27 
Altogether, these results imply that other factors such as race, disease severity, specific β 
blocker, and phenotype may interact with pharmacogenomic associations. In addition, SNPs 
may interact with each other and attenuate the elucidation of these associations.
Despite these challenges (or perhaps because of them), the pharmacogenetics of β blockers 
in heart failure continues to be an active area of investigation in recent years. Further work 
has attempted to sort out these inconsistencies, validate findings, and fully characterize the 
subset of optimal responders to β blocker therapy. An approach that continues to be used to 
address contradictions in the literature is the investigation of associations between genetic 
combinations and response to β blocker therapy, rather than individual polymorphisms. 50 
This strategy has been adopted by multiple investigators in recent years. Petersen et al. 
observed that heart failure patients who were homozygous for ADRB Arg389 and carriers of 
ADRB2 Gln27 in combination received less survival benefit from carvedilol treatment. 51 In 
contrast, this genotype combination did not impact response to metoprolol, likely due to 
differences in pharmacological properties. 51 More recently, O’Connor et al. have further 
elucidated the interaction of multiple adrenergic polymorphisms on β blocker response with 
another genetic substudy in BEST.52 In particular they reported an additive loss of 
bucindolol response in terms of morbidity and mortality in carriers of β1 Gly389 and 
α2C322–325 Del alleles, consistent with the effects of the individual SNPs on bucindolol 
response. 52 And an even more recent BEST substudy shows that genotype combinations 
determined from β1 Gly389 and α2C322–325 Del interact with response to bucindolol in 
terms of its efficacy in preventing ventricular arrhythmias in heart failure patients53; this 
morbidity response to bucindolol is similar to the abovementioned mortality response when 
using the same SNP combinations. Another important issue that is often overlooked in heart 
failure pharmacogenomic studies involves the impact of other comorbidities. This issue has 
been recently explored as well. In a substudy of BEST, atrial fibrillation status did not affect 
response to bucindolol. β1 Arg389 homozygote patients, but not β1 Gly389 carriers, had 
reduced death and hospitalization from bucindolol; which confirms the pharmacogenomic 
association discovered in the full BEST genetic population. 54 On the contrary, atrial 
fibrillation history impacted genetic response to β blockers in a population of elderly 
patients (age > 65) with heart failure. 55 Patients who were β1 Arg389 homozygotes and also 
suffered from atrial fibrillation had blunted heart rate reduction from carvedilol, but not 
bisoprolol; no attenuation in response to therapy was seen with patients in normal sinus 
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rhythm regardless of β blocker or genotype 55 demonstrating that comorbidities may interact 
with pharmacogenetic associations. Indeed β blocker response to adrenergic polymorphisms 
in acute myocardial infarction patients conflict with those seen in heart failure patients.56 In 
addition to these studies which look at the impact of gene-gene interactions and 
comorbidities on pharmacogenomic associations, investigators continue to report data on 
individual polymorphisms. In a prospectively recruited population of heart failure patients, 
Talameh et al. showed that β1 Ser49Ser homozygotes, but not Gly49 carriers, had enhanced 
survival response to β blocker therapy, using a larger population to corroborate previous 
findings that β blocker therapy has a greater influence on outcomes only in patients with 
Ser49Ser genotype. 31,57 Another recent genetic substudy looked at the impact of genotype 
on dose response in heart failure patients receiving metoprolol or carvedilol. 58 β1 Arg389 
homozygote patients had increased mortality and worsened quality of life from lower β 
blocker doses, whereas dose did not affect outcomes in Gly389 carriers. 58 This contribution 
is significant, because few have assessed quality of life outcomes or gene-dose response in 
pharmacogenomic heart failure studies. 58 Collectively, these recent findings indicate that 
while progress in this field continues, more work is still needed before clinical utility of β 
blocker pharmacogenomics can be achieved. At the current rate, this goal does not seem 
achievable in the near future; a heightened effort is warranted.
DRUGS TARGETING THE RENIN-ANGIOTENSIN-ALDOSTERONE SYSTEM
The RAAS also plays a key role during the development and worsening of heart failure. 59 
Several classes of agents for heart failure are available that work at different sites within the 
RAAS to suppress its effects. In particular, ACE inhibitors help to comprise the cornerstone 
of modern heart failure pharmacotherapy and have compelling evidence of survival benefit 
in multiple clinical trials. 60,61 ACE inhibitors act by blocking ACE-mediated conversion of 
angiotensin I to angiotensin II, thereby reducing vasoconstriction, salt-retention, and 
hypertrophy that occur with this neurohormone. 62 Genetic modifiers of ACE inhibitor 
effectiveness have been long sought with some early success. An insertion (I)/deletion (D) 
polymorphism in ACE is responsible for half of the variance in systemic ACE levels; the D 
allele is associated with increased ACE. 63 The presence of this variant is also associated 
with heart failure incidence and severity. 64,65 Additionally, past research has shown that 
this polymorphism alters response to ACE inhibitors. Cuoco et al. showed in a population of 
heart failure patients (90% receiving ACE inhibitors) that carriers of the D allele had 
significantly improved LVEF compared to wild-type patients after a mean follow-up of ~39 
months. 66 In contrast, in a population of patients with left ventricular hypertrophy and 
hypertension receiving ACE inhibitors, patients with the D/D genotype had less 
improvement in hypertrophy. 67 In a third study, the presence of the D allele had no impact 
on mortality in diastolic heart failure patients who received ACE inhibitors. 68 This finding 
that does not concur with either of the above results, but does agree with an earlier study in 
systolic heart failure patients that also showed a diminished impact of the polymorphism on 
outcomes in patients receiving ACE inhibitor therapy, specifically at higher doses. 69
Currently, the pharmacogenomic impact of ACE genetic variation in heart failure remains a 
controversial subject. In a recent genetic substudy of a randomized trial investigating the 
impact of pharmacist intervention on outcomes in heart failure patients (68% receiving ACE 
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inhibitors and 13% receiving ARBs at baseline), the ACE I/D polymorphism was not found 
to be associated with the composite of ED visits and hospitalizations. 70 Further work, 
including the resolution of the aforementioned conflicting data, is necessary to elucidate the 
potential application of using of pharmacogenomic information to guide the therapeutic 
regimen of RAAS drugs in heart failure.
OTHER HEART FAILURE THERAPIES
Guidelines recommend additional therapy as adjuncts to β blockers and ACE inhibitors for 
relieving symptoms, delaying the progression of cardiac dysfunction, and improving 
survival in heart failure patients. 7,8 Among others, adjunct therapies with the most 
promising pharmacogenetic evidence are digoxin and loop diuretics.
It is fairly well established that digoxin reduces symptoms of heart failure and 
hospitalizations. 10 Digoxin has been used for centuries in heart failure and continues to be 
recommended in this population, but only at doses that correlate with relatively low serum 
levels due to increased mortality at higher levels. 7,71 Given this narrow therapeutic range, 
factors which impact digoxin concentration may have important clinical implications. P-
glycoprotein which is coded by ABCB1 plays a role in digoxin elimination.72 The TTT 
haplotype is a combination of three SNPs (the substitution of thymine at positions 1236, 
2677, and 3435) in ABCB1 that are highly linked and have been found to be associated with 
digoxin serum levels. 73 In particular, a 2008 study reported that the TTT haplotype was 
associated with increased digoxin levels in a population of elderly Caucasian patients 
receiving digoxin. 73 This contrasts an earlier study that evaluated this association in a small 
population of heart failure patients did not find a significant ABCB1effect on digoxin 
levels, 74 suggesting that further work investigating the pharmacogenetics of digoxin is 
needed. This area continues to be investigated; a recent study confirms that the ABCB1 TTT 
haplotype may be predictive of elevated digoxin concentrations in patients receiving this 
medication, especially in females. 75 However, similar to the 2008 digoxin report 
mentioned, this 2012 study did not include a population of exclusively heart failure patients. 
The negative finding in heart failure patients hint that perhaps clinical or other factors 
related to the disease state may override any genetic association altering digoxin response. 
Validation in a larger independent population is necessary to establish if there is a genetic 
link to digoxin levels and clinical response in heart failure patients receiving digoxin.
Loop diuretics, similar to digoxin, have not been found to have a mortality benefit but are 
the most common agents used for symptomatic relief due to sodium and water retention. 
They act by inhibiting sodium-potassium-chloride luminal transporters in the loop of Henle 
causing an attenuation of the reabsorption of sodium and water. 76 Recently a small study in 
healthy volunteers suggests that genetics may play a clinically-relevant role in response to 
loop diuretics. 77 Polymorphisms in GNB2, ANP, ACE, and ADD1 impacted the excretion 
amounts of sodium chloride, potassium, and calcium. 77 Similar to the pharmacogenetics of 
digoxin, further work including confirmation in heart failure patients and a link to clinical 
efficacy is a necessary fundamental to understand if clinical application is possible.
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FUTURE PROSPECTS FOR PHARMACOGENOMICS
Over the past 15 years the field of pharmacogenetics has spread to include therapy for heart 
failure. Since the earliest periods of discovery, β blocker pharmacogenomics has been the 
most heavily explored, however response to other heart failure therapies also have shown 
the potential to be impacted by genotype. Taken together, the knowledge base summarized 
above demonstrates that genetic information does have the potential to guide therapeutic 
regimens for patients with heart failure and to improve outcomes. Despite this wealth of 
investigation, however, the pharmacogenomics of heart failure therapies still have not 
reached clinical utility. Additional steps are needed before this can be realized.
First, clarifying the current areas of inconsistency between gene-drug response associations 
should be a high priority. These inconsistencies suggest that complex genetic and 
environmental factors play a role. There needs to be a continued focus on the creation of 
‘polygenic profiles’ which serve as novel biomarkers for the response to heart failure 
medications and allows for the identification of ‘full’, ‘intermediate’, and ‘non-’ responder 
subsets. Additionally the consideration of comorbidities and other clinical factors are 
beginning to show utility in predicting which subsets of the heart failure population would 
respond best to certain agents; these results require further exploration.
Secondly, much emphasis has been placed on genes related to the adrenergic system as 
expected considering its great promise in predicting response to β blockers in clinical 
practice. Nonetheless, more attention needs to be placed on emerging pharmacogenetic 
biomarkers. In addition to the aforementioned pharmacogenetic findings that have been 
investigated in the past couple years involving ACE inhibitors, digoxin, and loop diuretics, 
novel genetic biomarkers in the early phases of discovery have potential to determine drug 
response in the heart failure population. For example, a recent study has shown that 
variation in genes coding for matrix metalloproteinases may interact with response to 
therapies altering the risk of heart failure development in hypertension patients. 78 
Furthermore, novel genetic biomarkers have the potential to predict response to heart failure 
therapies beyond pharmacological agents. De Maria et al. recently found that among heart 
failure patients receiving CRT, those who did not achieve clinically significant reverse 
remodeling were more likely to have the NR3C2 minor C allele (rs5522 C/T) compared to 
patients who achieved reverse remodeling. 79 These data, of course require validation, but 
overall, support the potential of emerging genetic predictors of response to both 
pharmacological and non-pharmacological treatment in the early development as well as the 
advanced progression of heart failure.
Another important step is the continued and expanded use of genetic analyses of heart 
failure randomized clinical trials (Table). These datasets serve as critical platforms to 
determine pharmacogenetic associations because they can supply large cohorts in which the 
impact of the therapy-gene interaction on outcomes can be most clearly demonstrated. 
Although genetic substudies are limited when the initial intervention has already become 
standard of care since this may preclude replication in an independent population, alternates 
for the validation of pharmacogenomic findings exist; these are beyond the scope of this 
review and are reviewed in great depth elsewhere. 80 Furthermore, these types of studies are 
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ideal for emerging therapies where they may aid in identifying the best responders to a 
therapy and reduce the probability of drug development failure in clinical trials. As a result 
of genetic substudies of BEST that have provided a wealth of knowledge, bucindolol may be 
the most auspicious candidate to be approved as a heart failure therapy that incorporates a 
pharmacogenomic-guided strategy. While genetic information is now routinely being 
collected in clinical trials worldwide 81,82, it is not always being actively utilized or opened 
for exploration, squandering many great opportunities.
Ultimately randomized clinical studies of pharmacogenomic-guided therapy would be 
needed to conclusively establish the utility of a pharmacogenomic approach in a clinical 
setting. The authors feel that one pharmacogenetic clinical trial success in heart failure 
would invigorate interest and open the flood gates for future studies. On the other hand, 
while randomized clinical trials represent the definitive proof, it is not a practical endeavor 
for each genetic variant and drug of potential interest. Indeed efforts to incorporate 
pharmacogenomic-guided decision making at the bedside at progressive institutions are 
taking place without the evidence of randomized, prospective trials.83–85 The medical and 
scientific community still needs to grapple with and decide on the level of evidence required 
for universal integration of heart failure pharmacogenomics in clinical practice.
In conclusion, progress in the field of heart failure pharmacogenetics continues, but further 
research is necessary. A collective and concerted effort between basic, clinical, and 
translational researchers is merited to achieve its incorporation into guidelines as a standard 
of clinical care.
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